Hepatitis C Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Hepatitis C stocks.

Hepatitis C Stocks Recent News

Date Stock Title
Nov 21 BMY Major companies that are also popular short-selling stocks
Nov 21 BMY Is Bristol Myers Squibb Stock a Buy?
Nov 21 BMY Want Over $3,000 in Annual Dividends? Invest $20,000 in Each of These 3 Stocks
Nov 20 UTHR Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Nov 19 BMY Bristol-Myers Squibb Company (BMY) Jefferies London Healthcare Conference (Transcript)
Nov 19 BMY Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms
Nov 18 BMY Encouraging Early Data From Next-Gen Study Puts Bristol Myers' CAR T Therapy In The Spotlight For Autoimmune Diseases
Nov 18 BMY Is Bristol-Myers Squibb Company (BMY) the Best Immunotherapy Stock to Buy Now?
Nov 18 BMY EMA’s CHMP to approve BMS’ Opdivo for colorectal cancer
Nov 17 BMY Bristol-Myers Squibb: Buy This Bargain Before It's Gone
Nov 17 BMY Large Pension Doubled Palantir Stake, Bought Up Intel and CVS Stock
Nov 15 UTHR United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy
Nov 15 BMY Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS
Nov 15 BMY Bristol Myers gets positive EMA opinion for repotrectinib
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer
Nov 15 UTHR United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom
Nov 15 BMY Bristol Myers Squibb Receives Positive CHMP Opinion for Repotrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer and Advanced NTRK-Positive Solid Tumors
Nov 14 BMY Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug
Hepatitis C

Hepatitis C is an infectious disease caused by the hepatitis C virus (HCV) that primarily affects the liver. During the initial infection people often have mild or no symptoms. Occasionally a fever, dark urine, abdominal pain, and yellow tinged skin occurs. The virus persists in the liver in about 75% to 85% of those initially infected. Early on chronic infection typically has no symptoms. Over many years however, it often leads to liver disease and occasionally cirrhosis. In some cases, those with cirrhosis will develop complications such as liver failure, liver cancer, or dilated blood vessels in the esophagus and stomach.HCV is spread primarily by blood-to-blood contact associated with intravenous drug use, poorly sterilized medical equipment, needlestick injuries in healthcare, and transfusions. Using blood screening, the risk from a transfusion is less than one per two million. It may also be spread from an infected mother to her baby during birth. It is not spread by superficial contact. It is one of five known hepatitis viruses: A, B, C, D, and E. Diagnosis is by blood testing to look for either antibodies to the virus or its RNA. Testing is recommended in all people who are at risk.There is no vaccine against hepatitis C. Prevention includes harm reduction efforts among people who use intravenous drugs and testing donated blood. Chronic infection can be cured about 95% of the time with antiviral medications such as sofosbuvir or simeprevir. Peginterferon and ribavirin were earlier generation treatments that had a cure rate of less than 50% and greater side effects. Getting access to the newer treatments however can be expensive. Those who develop cirrhosis or liver cancer may require a liver transplant. Hepatitis C is the leading reason for liver transplantation, though the virus usually recurs after transplantation.An estimated 143 million people (2%) worldwide are infected with hepatitis C as of 2015. In 2013 about 11 million new cases occurred. It occurs most commonly in Africa and Central and East Asia. About 167,000 deaths due to liver cancer and 326,000 deaths due to cirrhosis occurred in 2015 due to hepatitis C. The existence of hepatitis C – originally identifiable only as a type of non-A non-B hepatitis – was suggested in the 1970s and proven in 1989. Hepatitis C infects only humans and chimpanzees.

Browse All Tags